Brief: Akebia Therapeutics Enters Into License Agreement With Medice Arzneimittel Pütter GmbH&Co.KG For The Commercialization Of Vafseo For The Treatment Of Anemia Associated With CKD In Europe And Australia

Akebia Therapeutics

25/05/2023 13:48

May 25 (Reuters) - Akebia Therapeutics Inc  AKBA.O :
    * AKEBIA THERAPEUTICS ENTERS INTO LICENSE AGREEMENT WITH
MEDICE
ARZNEIMITTEL PÜTTER GMBH&CO.KG FOR THE COMMERCIALIZATION OF
VAFSEO® FOR THE TREATMENT OF ANEMIA ASSOCIATED WITH CKD IN
EUROPE AND AUSTRALIA
    * AKEBIA THERAPEUTICS INC - AKEBIA TO RECEIVE A $10 MILLION
UPFRONT PAYMENT, POTENTIAL FOR UP TO $100 MILLION IN COMMERCIAL
MILESTONE PAYMENTS
    * AKEBIA THERAPEUTICS INC - CO RETAINS MAJORITY OF ECONOMICS
IN
NON-DIALYSIS INDICATION IF APPROVED BY EMA AND RETAINS RIGHTS TO
ALL OTHER INDICATIONS
    * AKEBIA THERAPEUTICS INC - EXCLUSIVE LICENSE AGREEMENT
GRANTS
MEDICE RIGHTS TO MARKET AND SELL VAFSEO IN EUROPEAN ECONOMIC
AREA
    * AKEBIA THERAPEUTICS INC - AKEBIA WILL RECEIVE TIERED
ROYALTIES
FROM 10% TO 30% OF NET SALES
    * AKEBIA THERAPEUTICS INC - UNDER AGREEMENT, AKEBIA HAS
RIGHT TO
DEVELOP VAFSEO FOR USE AS A TREATMENT OF ANEMIA DUE TO CKD IN
ADULTS NOT ON DIALYSIS
    * AKEBIA THERAPEUTICS INC - AKEBIA RETAINS RIGHTS TO
VADADUSTAT
FOR ALL OTHER INDICATIONS

Source text for Eikon:  ID:nPn2N12Lfa 
Further company coverage:  AKBA.O 

 ((reuters.briefs@thomsonreuters.com;))